EUVIMEDEUVIMED entdecken
Delphi-StudieOpen Access

Consensus‐based clinical and research recommendations for use of glucagon‐like peptide‐1 receptor agonists in the context of eating disorders: a modified Delphi study

Aaron Keshen, Elena Koning, Kelly C Allison, Anastassia Amaro, Sara Bartel, Pauline Belliveau, Lisa Boniferro, Simran Brar, Sonia Butalia, Cynthia M Bulik, Ariana M Chao, Jennifer Couturier und 33 weitere

World Psychiatry · 2026-10 · 25 (3) · 465-474

DOI: 10.1002/wps.70096 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift World Psychiatry, online erschienen am 15.09.2026. Verfasst von Aaron Keshen und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Dalhousie University, Halifax, NS, Canada. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), initially developed for type 2 diabetes management and later expanded to obesity treatment, have shown preliminary efficacy in reducing binge eating episodes. However, the appetite‐suppressing and weight‐loss effects of GLP‐1RAs raise concerns about misuse and potential exacerbation or emergence of eating disorders (EDs). Evidence remains limited and inconsistent, requiring structured, expert‐informed guidance. Using a modified three‐round Delphi method, a multidisciplinary panel of experts in diabetes, obesity and/or EDs, and individuals with lived experience of an ED and/or GLP‐1RA use (N=45) achieved ≥70% consensus on recommendations (average consensus: 91.7%). Clinical recommendations include: a) the implementation of screening for current and historical ED before initiating GLP‐1RAs, using a brief psychometrically validated instrument; b) routine monitoring of ED symptoms with intensity stratified by risk level; c) the development of standardized educational materials for patients and providers; and d) offering concurrent evidence‐based psychotherapy to individuals with EDs prescribed GLP‐1RAs. These medications should generally be avoided in individuals with active EDs, particularly anorexia nervosa, atypical anorexia nervosa, and bulimia nervosa with marked dietary restraint and/or significant weight suppression. Clinicians should also proceed cautiously in patients with a past history of these EDs. Research recommendations include: a) longitudinal epidemiological studies to assess the incidence, risk factors, and outcomes of EDs in individuals using GLP‐1RAs compared to non‐users; b) regulatory studies and policies to enhance patient safety in GLP‐1RA prescribing practices; and c) clinical trials to investigate the safety, efficacy and psychological outcomes of GLP‐1RAs in individuals with binge eating disorder. Overall, these consensus‐based recommendations support evidence‐informed practice and future research aimed at weighing potential benefits against risks of use of GLP‐1RAs in ED populations.

Schlagwörter

Stichwörter der Autor:innen

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs)appetite‐suppressing effectsbinge eating episodesconsensus‐based recommendationseating disorderspatient safety

Autor:innen und Institutionen

  • Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.
  • Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania, Philadelphia, PA, USA.
  • Nova Scotia Provincial Eating Disorder Service, Nova Scotia Health, Halifax, NS, Canada.
  • McGill University Health Center, Montreal, QC, Canada.
  • Independent Social Work Practitioner, London, ON, Canada.

Zitieren

APA

Keshen, A., Koning, E., Allison, K. C., Amaro, A., Bartel, S., Belliveau, P., Boniferro, L., Brar, S., Butalia, S., Bulik, C. M., Chao, A. M., Couturier, J., Dennis, K., Dixon, L., El-Ziftawi, D., Gao, C., Gamberg, S., Goldstone, A. P., Dalle Grave, R., …, & Wnuk, S. (2026). Consensus‐based clinical and research recommendations for use of glucagon‐like peptide‐1 receptor agonists in the context of eating disorders: a modified Delphi study. World Psychiatry, 25(3), 465-474. https://doi.org/10.1002/wps.70096

Vancouver

Keshen A, Koning E, Allison KC, Amaro A, Bartel S, Belliveau P, et al. Consensus‐based clinical and research recommendations for use of glucagon‐like peptide‐1 receptor agonists in the context of eating disorders: a modified Delphi study. World Psychiatry. 2026;25(3):465-474. doi:10.1002/wps.70096

BibTeX
@article{Keshen2026,
  author = {Keshen, Aaron and Koning, Elena and Allison, Kelly C and Amaro, Anastassia and Bartel, Sara and Belliveau, Pauline and Boniferro, Lisa and Brar, Simran and Butalia, Sonia and Bulik, Cynthia M and Chao, Ariana M and Couturier, Jennifer and Dennis, Kimberly and Dixon, Laura and El-Ziftawi, Deena and Gao, Chloe and Gamberg, Susan and Goldstone, Anthony P and Dalle Grave, Riccardo and Guerdjikova, Anna I and Halliday, Tanya M and Hahn, Margaret and Harris, Anastasia and Himmerich, Hubertus and Horton, William B and Jericho, Monique and Langman, Brooke and Lightbody, Amanda and Klein, Diane A and Mayer, Laurel E S and McElroy, Susan L and Mindrum, Michael and Peiper, Nicholas C and Price, Colby and Raffoul, Amanda and Richards, Jesse and Schaefer, Lauren M and Steinglass, Joanna and Taylor, Valerie H and Tchang, Beverly G and Trappenberg, Nami and Walsh, B Timothy and Weintraub, Michael A and White, Ashley and Wnuk, Susan},
  title = {Consensus‐based clinical and research recommendations for use of glucagon‐like peptide‐1 receptor agonists in the context of eating disorders: a modified Delphi study},
  journal = {World Psychiatry},
  year = {2026},
  volume = {25},
  number = {3},
  pages = {465--474},
  doi = {10.1002/wps.70096}
}
Kostenlos starten →